Compare NOG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | CLDX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2008 |
| Metric | NOG | CLDX |
|---|---|---|
| Price | $21.48 | $25.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $29.86 | ★ $44.10 |
| AVG Volume (30 Days) | ★ 2.4M | 763.6K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 8.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,050,402,000.00 | $2,599,000.00 |
| Revenue This Year | $20.20 | N/A |
| Revenue Next Year | N/A | $19.70 |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $19.88 | $14.40 |
| 52 Week High | $42.35 | $30.50 |
| Indicator | NOG | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 44.96 |
| Support Level | $21.41 | $24.97 |
| Resistance Level | $22.74 | $28.79 |
| Average True Range (ATR) | 0.91 | 1.36 |
| MACD | -0.25 | -0.36 |
| Stochastic Oscillator | 1.64 | 16.46 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.